Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Britain said it was in advanced talks to access an experimental COVID-19 vaccine developed by Moderna Inc, which interim data on Monday indicated was 94.5% effective.

UK in talks to access Moderna vaccine from spring 2021 at the earliest

Early signs are encouraging, but we need to let the science take its time and not get our hopes too high yet. Last week the world got a big dose of promising news: Pharma giant Pfizer announced early results showing its COVID-19 vaccine was effective in more than 90% of the people who received it.

Moderna's COVID-19 vaccine: 5 things you need to know

US-based biotech firm is latest to reveal impressive results from phase 3 trials of jab

Moderna Covid vaccine candidate almost 95% effective, trials show

Moderna said its experimental coronavirus vaccine was nearly 95 percent effective in a pivotal study, adding to hopes that an inoculation for the deadly virus could be available soon. The biotech firm's Monday announcement made it the second major vaccine candidate to reveal promising early data from a late-stage clinical trial, just a week after.

Moderna COVID-19 vaccine nearly 95 percent effective in trial, firm says

The European Commission said the positive results announced on Monday by U.S. biotech firm Moderna for its COVID-19 vaccine candidate was encouraging and said the bloc was working to sign more supply deals with vaccine makers.

EU welcomes Moderna vaccine result, says more supply deals to come

Moderna (NASDAQ: MRNA) announced on Monday the results from phase 3 trials for the COVID-19 vaccine show the vaccine is 94.5% effective. This comes just one week after Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) vaccine candidate showed a 90% efficacy rate.

Moderna's Phase 3 COVID-19 Vaccine Shows 95% Efficacy

Moderna Inc (NASDAQ: MRNA) is now the second company to report the preliminary results from a large trial in the testing of a coronavirus vaccine. And Moderna said that the vaccine was 94.5% effective.

Moderna Inc (MRNA) Reports Coronavirus Vaccine Is 94.5% Effective

Pfizer announced last week that its vaccine has shown 90% efficacy in preventing the disease.

Moderna's Covid-19 Vaccine Is More Than 94% Effective, Preliminary Data Shows

Moderna's stock leapt as much as 9% in pre-market trading on Monday after the company announced its vaccine candidate is officially 94.5% effective. The US drugmaker said it was informed by the Data Safety Monitoring Board that its vaccine, mRNA-1273, has met the statistical criteria required for the study.

Moderna leaps 9% in premarket after results show its COVID-19 vaccine is almost 95% effective

Following fast on the heels of Pfizer's announcement of its COVID-19 vaccine efficacy, Moderna is also sharing positive results from its Phase 3 trial on Monday. The biotech company says that its COVID-19 vaccine candidate has shown efficacy of 94.5% in its first interim data analysis, which covers 95 confirmed COVID cases among its study […]

Moderna reports its COVID-19 vaccine is 94.5% effective in first data from Phase 3 trial

A coronavirus vaccine will be widely available in the US to any adult who wants it by the start of summer, Moderna CEO Stephane Bancel predicted Sunday. "What I believe is that by Memorial Day, in the US, anybody who wants a vaccine will get a safe and efficacious vaccine," Bancel said in an interview with Business Insider. Memorial Day, the US holiday that marks the unofficial start of summer, takes place on May 31 next year.

The CEO of Moderna says every American will likely have access to a COVID-19 vaccine by June 2021

Moderna Inc said on Monday its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations.

Instant View: Moderna says its vaccine is 94.5% effective in preventing COVID-19

Moderna Inc. shares soared 12% in premarket trade Monday, after the biotech said its COVID-19 vaccine candidate met its primary endpoint in a Phase 3 trial, demonstrating 94.5% efficacy. The company said it plans to submit an Emergency Use Authorization with the U.S. Food and Drug Administration in the coming weeks and expects it to be based on the final analysis of 151 cases and a median follow-up for more than two months.

Moderna shares soar premarket after COVID-19 vaccine candidate achieves 94.5% efficacy in Phase 3 trial

Shares of Moderna Inc. shot up 11% in premarket trading Monday, after the biotechnology company said its COVID-19 vaccine candidate mRNA-1273 now remains stable at refrigerated temperatures for longer times. The company said mRNA-1273 can now remain stable at 2 degrees to 8 degrees Celsius (36 degrees to 46 degrees Fahrenheit), which is the temperature of a standard home refrigerator, for 30 days, an extension from an earlier estimate of seven days.

Moderna's COVID-19 vaccine candidate can remain stable for longer in a standard refrigerator

Moderna said preliminary phase three trial data show its coronavirus vaccine is more than 94% effective in preventing Covid-19.

Moderna says preliminary trial data shows its coronavirus vaccine is more than 94% effective, shares soar

Moderna says its vaccine is 94.5% effective in preventing COVID-19

Moderna Inc's experimental COVID-19 vaccine is more stable than expected at temperatures that ordinary refrigerators can provide and can be distributed using existing cold-chain shipping and storage infrastructure.

Factbox: Moderna COVID-19 vaccine stability eases distribution challenges

Moderna's coronavirus vaccine proved 94.5% effective at an interim analysis of its final-phase test, the biotech company said early Monday. It's planning to seek authorization within weeks.

Moderna's Coronavirus Vaccine Proves 94.5% Effective In Key Test

We just took another big step forward in fighting the coronavirus pandemic.  Moderna on Monday said that its experimental vaccine was effective at preventing COVID-19, the disease caused by the novel coronavirus. The findings come from a massive and well-designed study, but they haven't been reviewed by outside experts or by regulators.

Moderna's coronavirus vaccine is effective at preventing COVID-19, joining Pfizer's shot. Here's what you need to know.

A second experimental coronavirus vaccine has succeeded at preventing COVID-19 in the final stage of clinical research, marking a victory in the fight against the pandemic. The upstart biotech Moderna announced the success Monday morning in a press release, saying its vaccine was 94.5% effective at preventing COVID-19, the disease caused by the novel coronavirus. An independent group of experts found clear signs of effectiveness after reviewing preliminary data from an ongoing 30,000-person study, Moderna said.

Moderna says its coronavirus vaccine is 94.5% effective against COVID-19, a crucial victory in the fight against the pandemic

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna's COVID-19 vaccine candidate meets its primary efficacy endpoint in the first interim analysis of the Phase 3 COVE study

Moderna's COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna announces longer shelf life for its COVID-19 vaccine candidate at refrigerated temperatures

Moderna Announces Longer Shelf Life for its COVID-19 Vaccine Candidate at Refrigerated Temperatures

A US-developed vaccine has been shown to be 94.5% effective at protecting people from COVID-19, according to interim results.

COVID-19: Moderna vaccine shown to be 94.5% effective and easier to store, according to interim analysis

Europe's health regulator said on Monday it had started a real-time review of Moderna Inc's experimental vaccine for COVID-19, on the back of similar such review launches for vaccines from AstraZeneca and Pfizer.

EMA starts rolling review for Moderna's COVID-19 vaccine candidate

BioNTech SE

Pfizer

The Editor-in-Chief of the British medical journal The Lancet explains why Pfizer and Moderna's approach is revolutionary.

News for Moderna Stock (MRNA)